87 results on '"Aleksandrova, E"'
Search Results
2. CLINICAL SIGNIFICANCE OF N-TERMINAL FRAGMENT OF NATRIURETIC PEPTIDE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO DO NOT RECEIVE PATHOGENETIC THERAPY
3. IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
4. LABORATORY BIOMARKERS FOR ANKYLOSING SPONDYLITIS
5. FAS APOPTOTIC GENE POLYMORPHISM (-670A/G) IS ASSOCIATED WITH CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS IN A RUSSIAN POPULATION: A PILOT STUDY
6. THE TIME COURSE OF CHANGES IN B LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING THERAPY WITH BIOLOGICAL AGENTS
7. AUTOANTIBODIES IN SYSTEMIC SCLEROSIS: SPECTRUM, CLINICAL ASSOCIATIONS, AND PROGNOSTIC VALUE
8. INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
9. Profile of autoantibodies in systemic sclerosis
10. USE OF SUBCUTANEOUS METHOTREXATE FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: THE REMARCA TRIAL
11. THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
12. INVESTIGATION OF A ROLE OF THE IMMUNOGENICITY OF INFLIXIMAB IN THE THERAPY OF ANKYLOSING SPONDYLITIS
13. CLINICAL VALUE OF BAFF AND APRIL CONCENTRATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
14. ROLE OF MATRIX METALLOPROTEINASE 3 IN PREDICTING THE EFFICIENCY OF THERAPY FOR EARLY RHEUMATOID ARTHRITIS: THE REMARCA TRIAL
15. PROBLEMS IN THE DIAGNOSIS AND TREATMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS: IN THE FOCUS OF ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS
16. TIME COURSE OF CHANGES IN BLOOD LIPID PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING TREAT-TO-TARGET ANTIRHEUMATIC THERAPY: ACCORDING TO 18-MONTH FOLLOW-UP FINDINGS
17. ASSESSMENT OF THE SENSITIVITY OF NEW CRITERIA FOR SYSTEMIC SCLEROSIS IN RUSSIAN PATIENT POPULATION
18. CHANGES IN CALPROTECTIN LEVEL, ITS RELATIONSHIP TO THE CLINICAL AND LABORATORY PARAMETERS OF DISEASE ACTIVITY AND SIGNIFICANCE FOR PREDICTING THE THERAPEUTIC RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT
19. AN ASSOCIATION OF CYTOKINE LEVELS WITH DISEASE ACTIVITY, AUTOANTIBODY LEVELS, AND JOINT DESTRUCTIVE CHANGES IN EARLY RHEUMATOID ARTHRITIS
20. IMPACT OF PREGNANCY ON THE ACTIVITY OF RHEUMATOID ARTHRITIS AND ITS THERAPY ACCORDING TO PROSPECTIVE FOLLOW-UP DATA
21. AUTOIMMUNE RHEUMATIC DISEASES: RESULTS AND PROSPECTS FOR RESEARCHES
22. ASSESSMENT OF RHEUMATOID ARTHRITIS ACTIVITY DURING PREGNANCY AND POSTPARTUM
23. CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS WITHIN THE REMARCA STUDY: PRELIMINARY DATA
24. IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE
25. ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
26. INTERLEUKIN-23 IN PATIENTS WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED SYSTEMIC VASCULITIDES: THE AUTHORS’ RESULTS AND A REVIEW OF LITERATURE
27. ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
28. THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
29. THE TIME COURSE OF CHANGES IN BIOMARKER LEVELS AND THE ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
30. USE OF MULTIPARAMETER ANALYSIS OF LABORATORY BIOMARKERS TO ASSESS RHEUMATOID ARTHRITIS ACTIVITY
31. USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME
32. THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
33. EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY
34. CLINICAL SIGNIFICANCE OF BAFF/BLyS AND APRIL IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
35. ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS
36. T-REGULATORY CELLS IN RHEUMATOID ARTHRITIS
37. PROCALCITONIN TEST IN RHEUMATIC DISEASES
38. CYTOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ASSOCIATION WITH LUNG INJURY
39. RITUXIMAB TREATMENT EFFICACY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REFRACTORY TO STANDARD THERAPY IN THE LONG-TERM FOLLOW-UP
40. RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
41. ELABORATION AND APPLICATION OF THE DIAGNOSTIC INDEX BASED ON MULTIVARIATE ANALYSIS OF BIOMARKERS TO DETERMINE THE ACTIVITY OF RHEUMATOID ARTHRITIS
42. THE CLINICAL SIGNIFICANCE OF MATRIX METALLOPROTEINASES IN RHEUMATOID ARTHRITIS PATIENTS (REVIEW OF THE LITERATURE AND OUR OWN DATA)
43. Varfarin in the complex treatment of antiphospholipid syndrome: preliminary results
44. ROLE OF INFLAMMATION MARKERS IN DEVELOPMENT OF ATHEROSCLEROSIS AND ITS COMPICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
45. IgG4-RELATED DISEASE. CLINICAL NOTES
46. CYTOKINE PROFILE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
47. EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
48. RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
49. Association of genetic markers with the efficiency of tocilizumab treatment for rheumatoid arthritis
50. Metabolic syndrome in rheumatoid arthritis: role of adiponectin (preliminary results)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.